Erratum: Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy (Eye (2013) 27 (253-264) DOI:10.1038/eye.2012.175);Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy

Eye (Basingstoke)

Volumn 27, Issue 2, 2013, Pages 253-264

  Shields, C L ^a   Fulco, E M ^a   Arias, J D ^a   Alarcon, C ^a   Pellegrini, M ^a   Rishi, P ^a   Kaliki, S ^a   Bianciotto, C G ^a   Shields, J A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chemoreduction; Intra arterial chemotherapy; Intravenous chemotherapy; Retinoblastoma; Tumour; Vitreous chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; ONDANSETRON; PROMETHAZINE; THIOTEPA; TOPOTECAN; VINCRISTINE;

BUPHTHALMOS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER PREVENTION; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DRUG FEVER; ECHOGRAPHY; ENUCLEATION; EXOPHTHALMOS; EXTERNAL BEAM RADIOTHERAPY; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE ANGIOGRAPHY; HUMAN; LEUKOKORIA; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; RETINA DETACHMENT; RETINOBLASTOMA; STRABISMUS; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

EID: 84874025398     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.218     Document Type: Erratum

References (69)

1. Ramasubramanian A, Shields CL. Epidemiology and magnitude of the problem. In: Ramasubramanian A, Shields CL (eds). Retinoblastoma. Jaypee Brothers Medical Publishers: New Delhi, India, 2012, pp 10-15
2. Shields JA, Shields CL. Retinoblastoma. In: Shields JA, Shields CL (eds). Intraocular Tumors. An Atlas and Textbook. 2nd ed. LippincottWilliamsWilkins: Philadelphia, PA, 2008, pp 293-365
3. Kivela T. The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93: 1129-1131
4. Shields CL, Shields JA. Retinoblastoma management: Advances in enucleation, intravenous chemoreduction, and intra-Arterial chemotherapy. Curr Opin Ophthalmol 2010; 21: 203-212
5. Shields CL, Kaliki S, Rojanaporn D, Al-Dahmash S, Bianciotto CG, Shields JA. Intravenous and intra-Arterial chemotherapy for retinoblastoma: What have we learned. Curr Opin Ophthalmol 2012; 23: 202-209
6. Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ, Boyd NW III. Presenting signs of retinoblastoma. J Pediatr 1998; 132: 505-508
7. Epstein J, Shields CL, Shields JA. Trends in the management of retinoblastoma; Evaluation of 1196 consecutive eyes during 1974-2001. J Pediatr Ophthalmol Strabismus 2003; 40: 196-203
8. Zhao J, Li S, Shi J, Wang N. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China. Br J Ophthalmol 2011; 95: 1072-1076
9. Ali AA, Elsheikh SM, Elhaj A, Osman N, Abuidris D, Eltayeb EA et al. Clinical presentation and outcome of retinoblastoma among children treated at the National Cancer Institute (NCI) in Gezira, Sudan: A single institution experience. Ophthalmic Genet, 2011; 32: 122-125
10. Boubacar T, Fatou S, Fousseyni T, Mariam S, Fatourmata DT, Toumeni S et al. A 30-month prospective study on the treatment of retinoblastoma in the Gabriel Toure Teaching Hospital, Bamako, Mali. Br J Ophthalmol 2010; 94: 467-469
11. Rodriguez-Galindo C, Wilson MW, Chantada G, Fu L, Qaddoumi I, Antoneli C et al. Retinoblastoma: One world, one vision. Pediatrics 2008; 122: E763-e770
12. Ramasubramanian A, Shields CL. Staging and treatment strategies. In: Ramasubramanian A, Shields CL (eds). Retinoblastoma. Jaypee Brothers Medical Publishers: New Delhi, India, 2012, pp 70-78
13. Reese AB, Ellsworth RM. The evaluation and current concePTof retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol 1963; 67: 164-172
14. Hopping W. The new Essen prognosis classification for conservative sight-saving treatment of retinoblastoma. In: Lommatzsch PK, Blodi FC (eds). Intraocular Tumors. International Symposium Under the Auspices of the European Ophthalmological Society. Springer-Verlag: Berlin, Germany, 1983, pp 497-505
15. Shields CL, Mashayekhi A, Demirci H, Meadows AT, Shields JA. Practical approach to management of retinoblastoma. Arch Ophthalmol 2004; 122: 729-735
16. Murphree AL. Intraocular retinoblastoma: The case for a new group classification. Ophthalmol Clin North Am 2005; 18: 41-53
17. Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006; 17: 228-234
18. Shields CL, Schoenfeld E, Kocher K, Shukla S, Kaliki S, Shields JA. Lesions simulating retinoblastoma (pseudoretinoblastoma) in 604 cases. Ophthalmology 2012, (in press
19. Shields CL, Shields JA. Intra-Arterial chemotherapy for retinoblastoma: The beginning of a long journey. Editorial. Clin Exp Ophthalmol 2010; 38: 638-643
20. Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996; 114: 1339-1343
21. Gallie BL, Budning A, DeBoer G, Thiessen JJ, Koren G, Verjee Z et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996; 114: 1321-1328
22. Murphree AL, Villablanca JG, Deegan WF, Sato JK, Malogolowkin M, Fisher A et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114: 1348-1356
23. Shields CL, DePotter P, Himelstein BP, Shields JA, Meadows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114: 1330-1338
24. Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ. Factors predictive of recurrence of retinal tumor, vitreous seeds and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002; 120: 460-464
25. Gombos DS, Kelly A, Coen PG, Kingston JE, Hungerford JL. Retinoblastoma treated with primary chemotherapy alone: The significance of tumor size, location and age. Br J Ophthalmol 2002; 86: 80-83
26. Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113: 2276-2280
27. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004; 9: 69-73
28. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008; 115: 1398-1404
29. Vajzovic LM, Murray TG, Aziz-Sultan MA, Schefler AC, Wolfe SQ, Hess D et al. Supraselective intra-Arterial chemotherapy: Evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol 2011; 5: 171-176
30. Shields CL, Bianciotto CG, Ramasubramanian A, Lally SE, Jabbour P, Griffin GC et al. Intra-Arterial chemotherapy for retinoblastoma. Report #1: Control of tumor, subretinal seeds, and vitreous seeds. Arch Ophthalmol 2011; 129: 1399-1406
31. Leahey AM. Systemic chemotherapy: A pediatric oncology perspective. In: Ramasubramanian A, Shields CL (eds). Retinoblastoma. Jaypee Brothers Medical Publishers: New Delhi, India, 2012, pp 81-85
32. Shields CL, Ramasubramanian A, Thangappan A, Hartzell K, Leahey A, Meadows AT et al. Chemoreduction (CRD) for group E retinoblastoma. Comparison of CRD alone versus CRD plus low dose external radiotherapy in 76 eyes. Ophthalmology 2009; 117: 544-551
33. Shields CL, Kaliki S, Al-Dahmash S, Rojanaporn D, Leahey A, Griffin G et al. Management of advanced retinoblastoma (group D or E) with primary intravenous chemotherapy followed by secondary intra-Arterial chemotherapy as an alternative to enucleation. Arch Ophthalmol 2012 (in press
34. Friedman DL, Himelstein B, Shields CL, Shields JA, Miller D, Needle M et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18: 12-17
35. Lambert MP, Shields CL, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 2008; 50: 223-226
36. Leahey A. A cautionary tale: Dosing chemotherapy in infants with retinoblastoma. J Clin Oncol 2012; 30: 1023-1024
37. Friedrich MJ. Retinoblastoma therapy delivers power of chemotherapy with surgical precision. JAMA 2011; 305: 2276-2278
38. Kaliki S, Shields CL, Shah SU, Eagle RC Jr, Shields JA, Leahey A. Postenucleation adjuvant chemotherapy with vincristine, etoposide and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol 2011; 129: 1422-1427
39. Demirci H, Shields CL, Meadows AT, Shields JA. Long-Term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol 2005; 123: 1525-1530
40. Narang S, Mashayekhi A, Rudich D, Shields CL. Predictors of long-Term visual outcome after chemoreduction for management of intraocular retinoblastoma. Clin Experiment Ophthalmol 2012; e-pub ahead of print 2 February 2012; doi: 10.1111/j.1442-9071.2012.02757.x.
41. Shields CL, Meadows AT, Shields JA, Carvalho C, Smith A. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 2001; 119: 1269-1272
42. Moll AC, Imhof SM, Schouten-Van Meeteren AY, Boers M, van Leeuwen F, Hofman P. Chemoreduction for retinoblastoma. Arch Ophthalmol 2003; 121: 1513
43. Usitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O'Brien JM. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001; 119: 41-48
44. Honavar SG, Singh AD, Shields CL, Meadows AM, Demirci H, Cater J et al. Post-enucleation adjuvant therapy in highrisk retinoblastoma. Arch Ophthalmol 2002; 120: 923-931
45. Eagle RC Jr. High-risk features and tumor differentiation in retinoblastoma: A retrospective histopathologic study. Arch Pathol Lab Med 2009; 133: 1203-1209
46. Wilson MW, Qaddoumi I, Billups C, Haik BG, Rodriguez-Gallindo C. A clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma. Br J Ophthalmol 2011; 95: 553-558
47. Kaliki S, Shields CL, Rojanaporn D, Al-Dahmash S, McLaughlin J, Shields JA et al. International classification of retinoblastoma predicts high-risk retinoblastoma: Analysis of 519 enucleated eyes. Ophthalmology 2012 (in press
48. Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, Dunkel IJ et al. Secondary acute myelogenous leukemia in patients with retinoblastoma. Is chemotherapy a factor? Ophthalmology 2007; 114: 1378-1383
49. Turaka K, Shields CL, Leahey A, Meadows AT. Second malignant neoplasms following chemoreduction for retinoblastoma in 272 patients. Pediatr Blood Cancer 2012; 59: 121-125
50. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-Arterial chemotherapy for the management of retinoblastoma: Four-year experience. Arch Ophthalmol 2011; 129: 732-737
51. Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS, Reddy MA. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatmen of refractory retinoblastoma. Ophthalmology 2012; 119: 611-616
52. Shields CL, Kaliki S, Shah SU, Bianciotto CG, Liu D, Jabour P et al. Minimal exposure (1 or 2 cycles) of intra-Arterial chemotherapy in the management of retinoblastoma. Ophthalmology 2012; 119: 188-192
53. Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, Binaghi S. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina 2011; 31: 566-573
54. Shields CL, Bianciotto CG, Jabbour P, Griffin GC, Ramasubramanian A, Rosenwasser R et al. Intra-Arterial chemotherapy for retinoblastoma. Report #2: Treatment complications. Arch Ophthalmol 2011; 129: 1407-1415
55. Bianciotto CG, Shields CL, Iturralde JC, Sarici A, Jabbour P, Shields JA. Fluorescein angiographic findings after intraarterial chemotherapy for retinoblastoma. Ophthalmology 2012; 119: 843-849
56. Wilson MW, Jackson JS, Phillips BX, Buchanan J, Frase S, Wang F et al. Real-Time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model. Arch Ophthalmol 2011; 129: 1458-1465
57. Wilson MW, Haik BG, Dyer MA. Superselective intraophthalmic artery chemotherapy. What we do not know. Arch Ophthalmol 2011; 129: 1490-1491
58. Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapy following systemic or local administration. Arch Ophthalmol 1998; 116: 1209-1212
59. Hayden BC, Jockovich ME, Murray TG, Voigt M, Milne P, Kralinger M et al. Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: Possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci 2004; 45: 3644-3649
60. Martin NE, Kim JW, Abramson DH. Fibrin sealant for retinoblastoma: Where are we? J Ocul Pharmacol Ther 2008; 24: 433-438
61. Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Grossniklaus HE. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol 2009; 127: 1043-1047
62. Abramson DH. Periocular chemotherapy for retinoblastoma: Success with problems? Arch Ophthalmol 2005; 123: 128-129
63. Mulvihill A, Budning A, Jay V, Vandenhoven C, Heon E, Gallie BL et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 2003; 121: 1120-1124
64. Ericson LA, Kalberg B, Rosengren BH. Trials of intravitreal injections of chemotherapeutic agents in rabbits. Acta Ophthalmol 1964; 42(4): 721-726
65. Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res 1987; 78(8): 858-868
66. Ueda M, Tanabe J, Inomata M, Kaneko A, Kimura T. Study on conservative treatment of retinoblastoma-effect of intravitreal injection of melphalan on the rabbit retina. Nippon Ganka Gakkai Zasshi 1995; 99: 1230-1235
67. Munier F, Gaillard MC, Balmer A, Soliman S, Podlisky G, Moulin AP et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to conditional indications. Br J Ophthalmol 2012; 96: 1078-1083
68. Kivelä T, Eskelin S, Paloheimo M. Intravitreal methotrexate for retinoblastoma. Ophthalmology 2011; 118: 1689
69. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol 2012 (in press